On the Record · Teva Pharmaceutical Industries
Teva Pharmaceutical Industries acquisitions, on the record
The businesses Teva Pharmaceutical Industries bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Novetide Ltd.Word for word“In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies.”” 10-K for 2023 | acquisition | January 2022 | — |
our business venture in Japan, which includes generic products and legacy productsWord for word“We expect to complete the divestiture by April 1, 2025, subject to standard closing conditions, including obtaining required regulatory approvals.” 10-K for 2024 | agreed divestiture | April 1, 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $36.15 billion | — | — |
| 2017-12-31 | −$43 million | — | — |
| 2019-12-31 | — | $343 million | — |
| 2020-12-31 | $0 | $67 million | — |
| 2021-12-31 | $0 | $311 million | — |
| 2022-12-31 | $7 million | $68 million | $12 million |
| 2023-12-31 | $0 | $68 million | — |
| 2024-12-31 | $15 million | $43 million | — |
| 2025-12-31 | $0 | $34 million | — |
Deal filings since 2016
- 2026-09-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-12-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-06-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-08-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-06-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-11-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-04-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-03-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-02-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Teva Pharmaceutical Industries’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-03. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.